{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:30:26Z","timestamp":1783729826860,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660024"],"award-info":[{"award-number":["81660024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["2020MS08096"],"award-info":[{"award-number":["2020MS08096"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inner Mongolia Autonomous Region Science and Technology Innovation Guidance Project","award":["KCBJ2018021"],"award-info":[{"award-number":["KCBJ2018021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The spermatogenesis associated serine rich 2 (SPATS2) is a member of RNA-binding protein in which the abnormal expression is linked with carcinogenesis in serval types of cancer. However, there is no systematic study on the differential expression, prognostic significance, epigenetic regulation, immune infiltration of SPATS2 in hepatocellular carcinoma (HCC). In the present study, we investigated the expression, prognosis, epigenetic regulation, and immune cell infiltration of SPATS2 in HCC. We found that the elevated expression of SPATS2 was unfavorably associated with the clinical pathological stage and prognosis. Functional enrichment analysis revealed that SPATS2 is associated with cell cycle, apoptosis and cancer cell metastasis processes in HCC. Our results confirmed that knockdown of SPATS2 will affect cell cycle, apoptosis and invasion of HCC cell lines. Moreover, the expression of SPATS2 is upregulated by epigenetic regulation, including DNA methylation, m6A and histone modification in HCC. In addition, SPATS2 expression was positively correlated with immune cell infiltration or expression of immune related gene markers in HCC. Taken together, our data demonstrated that SPATS2 is associated with progression and immune infiltration, and could serve as a prognostic biomarker for HCC. In conclusion, these results highlight the potential of SPATS2 to be used as a therapeutic target for HCC.<\/jats:p>","DOI":"10.1186\/s12876-022-02633-y","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T04:05:55Z","timestamp":1673409955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Jing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu ling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2633_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","volume":"27","author":"P Ganesan","year":"2023","unstructured":"Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27(1):85\u2013102. https:\/\/doi.org\/10.1016\/j.cld.2022.08.004. (Epub 2022 Oct 18).","journal-title":"Clin Liver Dis"},{"issue":"3","key":"2633_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cnc.2022.04.004","volume":"34","author":"H Gilles","year":"2022","unstructured":"Gilles H, Garbutt T, Landrum J. Hepatocellular carcinoma. Crit Care Nurs Clin North Am. 2022;34(3):289\u2013301. https:\/\/doi.org\/10.1016\/j.cnc.2022.04.004. (Epub 2022 Jul 20).","journal-title":"Crit Care Nurs Clin North Am"},{"issue":"16","key":"2633_CR4","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.3390\/cancers14164028","volume":"14","author":"C Laface","year":"2022","unstructured":"Laface C, Fedele P, Maselli FM, Ambrogio F, Foti C, Molinari P, Ammendola M, Lioce M, Ranieri G. Targeted therapy for hepatocellular carcinoma: old and new opportunities. Cancers (Basel). 2022;14(16):4028. https:\/\/doi.org\/10.3390\/cancers14164028.","journal-title":"Cancers (Basel)"},{"key":"2633_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11864-021-00886-5","volume":"22","author":"CAM Fulgenzi","year":"2021","unstructured":"Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Immunotherapy in hepatocellular carcinoma. Curr Treat Options Oncol. 2021;22:87. https:\/\/doi.org\/10.1007\/s11864-021-00886-5.","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"2633_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41419-020-03039-y","volume":"11","author":"G Dong","year":"2020","unstructured":"Dong G, Zhang S, Shen S, Sun L, Wang X, Wang H, Wu J, Liu T, Wang C, Wang H, Lu T, Rao B, Ren Z. SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle. Cell Death Dis. 2020;11(10):837. https:\/\/doi.org\/10.1038\/s41419-020-03039-y.","journal-title":"Cell Death Dis"},{"key":"2633_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1006\/bbrc.2002.6769","volume":"292","author":"M Senoo","year":"2002","unstructured":"Senoo M, Hoshino S, Mochida N, Matsumura Y, Habu S. Identification of a novel protein p59(scr), which is expressed at specific stages of mouse spermatogenesis. Biochem Biophys Res Commun. 2002;292:992\u20138. https:\/\/doi.org\/10.1006\/bbrc.2002.6769.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"2633_CR8","doi-asserted-by":"publisher","first-page":"13875","DOI":"10.1038\/ncomms13875","volume":"22","author":"ND Damas","year":"2002","unstructured":"Damas ND, Marcatti M, C\u00f4me C, Christensen LL, Nielsen MM, Baumgartner R, Gylling HM, Maglieri G, Rundsten CF, Seemann SE, Rapin N, Th\u00e9zenas S, Vang S, \u00d8rntoft T, Andersen CL, Pedersen JS, Lund AH. SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization. Nat Commun. 2016;22(7):13875. https:\/\/doi.org\/10.1038\/ncomms13875.","journal-title":"Nat Commun"},{"issue":"1","key":"2633_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3892\/etm.2021.10130","volume":"22","author":"YP Liu","year":"2021","unstructured":"Liu YP, Cao Q, Li L, Zhang M. High expression of spermatogenesis associated serine rich 2 promotes tumorigenicity in esophageal squamous cell carcinoma cells and is associated with poor patient prognosis. Exp Ther Med. 2021;22(1):698. https:\/\/doi.org\/10.3892\/etm.2021.10130.","journal-title":"Exp Ther Med"},{"key":"2633_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12885-016-2792-1","volume":"16","author":"K Takamochi","year":"2016","unstructured":"Takamochi K, et al. Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC Cancer. 2016;16:760. https:\/\/doi.org\/10.1186\/s12885-016-2792-1.","journal-title":"BMC Cancer"},{"issue":"9","key":"2633_CR11","doi-asserted-by":"publisher","first-page":"e19230","DOI":"10.1097\/MD.0000000000019230","volume":"99","author":"J Xing","year":"2020","unstructured":"Xing J, Tian Y, Ji W, Wang X. Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer. Medicine (Baltimore). 2020;99(9):e19230. https:\/\/doi.org\/10.1097\/MD.0000000000019230.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2633_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7150\/jca.47526","volume":"12","author":"L Chen","year":"2021","unstructured":"Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 suppresses proliferation and invasion of hepatocellular carcinoma cells through TRIM44-STAT3 signaling pathway. J Cancer. 2021;12(1):89\u201398. https:\/\/doi.org\/10.7150\/jca.47526.","journal-title":"J Cancer"},{"key":"2633_CR13","doi-asserted-by":"publisher","first-page":"793343","DOI":"10.3389\/fimmu.2021.793343","volume":"12","author":"ZH Wu","year":"2021","unstructured":"Wu ZH, Yang DL, Wang L, Liu J. Epigenetic and immune-cell infiltration changes in the tumor microenvironment in hepatocellular carcinoma. Front Immunol. 2021;12:793343. https:\/\/doi.org\/10.3389\/fimmu.2021.793343.","journal-title":"Front Immunol"},{"issue":"3","key":"2633_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","volume":"144","author":"V Hernandez-Gea","year":"2013","unstructured":"Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512\u201327. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.002.","journal-title":"Gastroenterology"},{"issue":"6377","key":"2633_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Boss\u00e9 D, Wankowicz SM, Cullen D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, NY). 2018;359(6377):801\u20136.","journal-title":"Science (New York, NY)"},{"issue":"10088","key":"2633_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela CC, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"key":"2633_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000812","author":"Z Macek Jilkovaa","year":"2021","unstructured":"Macek Jilkovaa Z, Ghelfi J, Decaens T. Immunomodulation for hepatocellular carcinoma therapy: current challenges. Curr Opin Oncol. 2021. https:\/\/doi.org\/10.1097\/CCO.0000000000000812.","journal-title":"Curr Opin Oncol"},{"issue":"21","key":"2633_CR18","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77(21):e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307.","journal-title":"Can Res"},{"issue":"21","key":"2633_CR19","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"CJ Liu","year":"2018","unstructured":"Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/bty411.","journal-title":"Bioinformatics"},{"issue":"20","key":"2633_CR20","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, Chan NW, Zhang J. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"key":"2633_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cancers12010077","volume":"12","author":"M Hilmi","year":"2019","unstructured":"Hilmi M, Vienot A, Rousseau B, et al. Immune therapy for liver cancers. Cancers (Basel). 2019;12:77. https:\/\/doi.org\/10.3390\/cancers12010077.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2633_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525\u201343. https:\/\/doi.org\/10.1038\/s41575-021-00438-0. (Epub 2021 Apr 13).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2633_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","volume":"135","author":"B Hoechst","year":"2008","unstructured":"Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kr\u00fcger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+) CD25(+) Foxp3(+) T cells. Gastroenterology. 2008;135:234\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2008.03.020.","journal-title":"Gastroenterology"},{"key":"2633_CR24","doi-asserted-by":"publisher","first-page":"846923","DOI":"10.3389\/fimmu.2022.846923","volume":"13","author":"E Bourayou","year":"2022","unstructured":"Bourayou E, Golub R. Signaling pathways tuning innate lymphoid cell response to hepatocellular carcinoma. Front Immunol. 2022;13:846923. https:\/\/doi.org\/10.3389\/fimmu.2022.846923.","journal-title":"Front Immunol"},{"key":"2633_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13537","author":"MZ Moghaddam","year":"2022","unstructured":"Moghaddam MZ, Ansariniya H, Seifati SM, Zare F, Fesahat F. Immunopathogenesis of endometriosis: an overview of the role of innate and adaptive immune cells and their mediators. Am J Reprod Immunol. 2022. https:\/\/doi.org\/10.1111\/aji.13537.","journal-title":"Am J Reprod Immunol"},{"key":"2633_CR26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342\u201356. https:\/\/doi.org\/10.1016\/j.cell.2017.05.035.","journal-title":"Cell"},{"key":"2633_CR27","doi-asserted-by":"publisher","first-page":"775462","DOI":"10.3389\/fcell.2021.775462","volume":"9","author":"X Hao","year":"2021","unstructured":"Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges. Front Cell Dev Biol. 2021;9:775462. https:\/\/doi.org\/10.3389\/fcell.2021.775462.","journal-title":"Front Cell Dev Biol"},{"key":"2633_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","volume":"7","author":"J Ma","year":"2019","unstructured":"Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, et al. PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7:331. https:\/\/doi.org\/10.1186\/s40425-019-0814-7.","journal-title":"J Immunother Cancer"},{"key":"2633_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers11040564","volume":"11","author":"L Wu","year":"2019","unstructured":"Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers. 2019;11:564. https:\/\/doi.org\/10.3390\/cancers11040564.","journal-title":"Cancers"},{"key":"2633_CR30","doi-asserted-by":"publisher","first-page":"e1356965","DOI":"10.1080\/2162402X.2017.1356965","volume":"6","author":"J Michaeli","year":"2017","unstructured":"Michaeli J, Shaul ME, Mishalian I, Hovav AH, Levy L, Zolotriov L, Granot Z, Fridlender ZG. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFalpha and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology. 2017;6:e1356965. https:\/\/doi.org\/10.1080\/2162402X.2017.1356965.","journal-title":"Oncoimmunology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02633-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02633-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02633-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T04:09:18Z","timestamp":1673410158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02633-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02633-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2106467\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TCGA and GEO belong to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open-source data, so there are no ethical issues and other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}